Lacosamide Vivanta (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing these channels, it reduces neuronal hyperexcitability and the likelihood of repetitive firing that leads to seizure activity, providing an anticonvulsant effect.

The dosing regimen for Lacosamide Vivanta is determined by the prescribing clinician based on the individual patient's clinical condition, age, renal function, and response to therapy. Specific dosage instructions are provided in the product’s prescribing information.

Safety data for Lacosamide in pregnancy and lactation are limited. The prescribing clinician should evaluate the potential benefits and risks before use in pregnant or nursing women, and consider alternative treatments when appropriate.

To order Lacosamide Vivanta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that block fast sodium channels or modulate GABA. This can offer complementary seizure control when used with other agents, though individual response and tolerability vary.

Lacosamide Vivanta should be stored at 2‑8 °C, protected from light, and must not be frozen. The product should be kept in its original packaging and handled according to standard aseptic techniques for intravenous medications.

Lacosamide Vivanta is administered intravenously by a healthcare professional. The infusion rate and duration are determined by the prescriber and should follow the guidelines in the product’s prescribing information to ensure safe and effective delivery.

Serious risks include cardiac arrhythmias such as PR‑interval prolongation, atrial fibrillation, severe skin reactions like Stevens‑Johnson syndrome, suicidal thoughts or behaviors, hepatic dysfunction, and profound hypotension. Patients should be monitored closely for these events.

Lacosamide Vivanta is contraindicated in patients with known hypersensitivity to Lacosamide or any excipients in the formulation. Caution is advised for individuals with significant cardiac conduction disorders, severe renal or hepatic impairment, and those taking interacting medications that affect sodium‑channel function.